SCHEMBL380758

SCHEMBL380758

O=C(O)NCCCCO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28168552 0.97 TDP1 (0.50)
SCHEMBL11050266 0.97 TDP1 (0.50)
SCHEMBL4235227 0.97 TDP1 (0.50)
SCHEMBL1310407 0.97 TDP1 (0.50)
SCHEMBL6253901 0.97 TDP1 (0.50)
SCHEMBL6253782 0.97 TDP1 (0.50)
SCHEMBL445647 0.97 TDP1 (0.50)
SCHEMBL6253810 0.97 TDP1 (0.50)
SCHEMBL629320 0.92
Hydrochloric Acid SCHEMBL4333850 0.89

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456311-B1 URETHANE POLYMERS THAT REDUCE THE EFFECT OF POLYLACTONE LINKAGES BASF COATINGS GMBH (DE) 2012-09-26 EP claimed
EP-1794203-B1 FUNCTIONAL ADDITION POLYMERS AND A METHOD FOR THEIR PREPARATION BASF CORP (US) 2011-06-08 EP claimed
EP-1456310-B1 ASYMMETRIC DIISOCYANATE MONOMERS IN URETHANE POLYMERS AND OLIGOMERS TO REDUCE CRYSTALLINITY BASF CORP (US) 2008-02-27 EP claimed
EP-1453921-B1 CLEARCOAT COMPOSITION BASF CORP (US) 2007-05-09 EP claimed
EP-1266900-A1 Carbamates of rapamycin Wyeth (US) 2002-12-18 EP claimed
CN-1091135-A The carbamate of Wyeth-Ayerst Laboratories AMERICAN HOME PROD (US) 1994-08-24 CN claimed
EP-0593227-A1 Carbamates of rapamycin AMERICAN HOME PRODUCTS CORPORATION (US) 1994-04-20 EP claimed
US-5302584-A Immunosuppressants AMERICAN HOME PRODUCTS CORPORATION (US) 1994-04-12 US claimed
WO-2024097948-A1 DEGRADERS OF MDM2 AND USES THEREOF ROIVANT DISCOVERY, INC. (US) 2024-05-10 WO disclosed
US-20240115711-A1 Novel Bifunctional Molecules For Targeted Protein Degradation AMPHISTA THERAPEUTICS LIMITED (GB) 2024-04-11 US disclosed
WO-2024065043-A1 AMINO ACID-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF THERAPEUTIC AGENTS NANOVATION THERAPEUTICS INC. (CA) 2024-04-04 WO disclosed
US-20240110015-A1 SUPRAMOLECULAR BIOMEDICAL POLYMERS SUPRAPOLIX B.V. (NL) 2024-04-04 US disclosed
WO-2024059808-A1 WEE1 INHIBITORS AND METHODS FOR TREATING CANCER RECURIUM IP HOLDINGS, LLC (US) 2024-03-21 WO disclosed
WO-2024052701-A1 NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 WO disclosed
CN-1143075-A 15-deoxyspergualin analogs, their method of preparation and their use in therapeutics FOURNIER IND & SANTE (FR) 1997-02-19 CN disclosed
US-5411967-A Antiinflammatory, immunosuppressant, antitumor AMERICAN HOME PRODUCTS CORPORATION (US) 1995-05-02 US disclosed
EP-0593227-A1 Carbamates of rapamycin AMERICAN HOME PRODUCTS CORPORATION (US) 1994-04-20 EP disclosed
US-5302584-A Immunosuppressants AMERICAN HOME PRODUCTS CORPORATION (US) 1994-04-12 US disclosed
EP-0207461-A2 Process for the preparation of omega-isocyanatoalkyl(meth)acrylates BASF Aktiengesellschaft (DE) 1987-01-07 EP disclosed
US-4331438-A TREATMENT WITH A FORMALDEHYDE ACCEPTOR BASF WYANDOTTE CORPORATION (US) 1982-05-25 US disclosed